<DOC>
	<DOCNO>NCT01424189</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness investigational multifocal toric intraocular lens ( IOL ) compare FDA-approved multifocal IOL .</brief_summary>
	<brief_title>Clinical Investigation AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens ( IOL )</brief_title>
	<detailed_description>Participants 21 year old within target astigmatism range need cataract extraction eye consent randomized 2:1 ratio investigative site receive either AcrySof® IQ ReSTOR® Multifocal Toric IOL control AcrySof® ReSTOR® Multifocal IOL eye . Each participant complete preoperative examination eye , implantation IOL operative visit eye , 8 postoperative visit , monocular test Day 1-2 , Day 7-14 , Day 30-60 binocular test Day 120-180 Day 340-420/Visit 5 follow second implantation . The eye great amount astigmatism implant first ( first operative eye ) . The second eye implant intend occur within 30 day first eye implant prior 7 day first eye implant . Both eye need qualify inclusion/exclusion criterion preoperative visit . If first eye exclude surgery , second eye eligible . If second eye exclude surgery , first eye follow .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<criteria>Diagnosed bilateral cataract ; Able comprehend sign statement inform consent ; Calculated lens power astigmatism within available range ; Willing able complete require postoperative visit ; Planned cataract removal phacoemulsification ; Potential postoperative visual acuity 0.2 logMAR well eye ; Preoperative astigmatism operative eye describe clinical protocol ; Note : Corneal incision make reduce astigmatism allow course study . Clear intraocular medium cataract study eye ; Preoperative Best Corrected Distance Visual Acuity ( BCDVA ) worse 0.2 logMAR eye ; Pupil size great equal 6 mm dilation ; Able undergo second eye surgery within 30 day first eye surgery ; Other protocolspecified inclusion criterion may apply . Significant irregular corneal aberration demonstrate corneal topography ; Keratopathy/Kerectasia corneal abnormality , regular corneal astigmatism ; Any inflammation edema ( swell ) cornea ; Diagnosed degenerative visual disorder ( e.g . macular degeneration retinal disorder ) predict ( subjective assessment retina ) cause future acuity loss level bad 0.2 logMAR ; Reasonably expect require secondary surgical intervention time study ( YAG capsulotomy ) ; Previous corneal refractive surgery ; Amblyopia ; Clinically severe corneal dystrophy ( e.g. , epithelial , stromal , endothelial dystrophy ) ; Diabetic retinopathy ; Extremely shallow anterior chamber , due swell cataract ; Microphthalmos ; Previous retinal detachment ; Previous corneal transplant ; Recurrent severe anterior posterior segment inflammation unknown etiology ; Rubella traumatic cataract ; Iris neovascularization ; Glaucoma ( uncontrolled control medication ) ; Aniridia ; Optic nerve atrophy ; Pregnancy ; Current participation another investigational drug device study may confound result investigation ; Other plan ocular surgery procedure , include , limited LASIK , astigmatic keratotomy limbal relaxing incision , duration study ; Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cataract surgery</keyword>
	<keyword>Intraocular lens</keyword>
</DOC>